IL1A and cryopyrin-associated periodic syndrome: The extracellular portion has a strong affinity for both IL-1α and IL-1β, thereby neutralising their activities and functioning as an “IL-1 trap”.127,128 It was approved by the FDA in 2008 for the treatment of cryopyrin-associated periodic syndromes (CAPS).